Phenobarbital and Drowning: Unraveling the Risks
"A deep dive into a case study that links epilepsy treatment with fatal drowning."
Phenobarbital, a long-standing medication used in the treatment of epilepsy, has been a subject of both praise and scrutiny. While it effectively manages seizures for many, a recent case study brings to light a concerning potential risk: drowning. Understanding this connection is crucial for both patients and healthcare providers.
The case study, documented in Reactions 1711, p252 and published on July 21, 2018, details a patient's tragic death due to drowning, which was found to be secondary to phenobarbital treatment for epilepsy. This raises important questions about the drug's side effects and the precautions necessary for those using it.
This article aims to dissect this case study, providing a comprehensive yet accessible explanation of the factors that link phenobarbital to an increased risk of drowning. We'll explore the drug's mechanism, potential side effects, and necessary safety measures to ensure patient well-being.
Current Role and Impact
Phenobarbital remains the most cost-effective pharmacologic treatment for epilepsy, according to a 2012 review. The same review predicts a healthy future for phenobarbital, particularly in helping close the treatment gap in low- and middle-income countries during its second century of clinical use. The CDC provides U.S. epilepsy data from 2021 and 2022, including active epilepsy prevalence by age, race and ethnicity, sex, employment status, education, and insurance coverage.
Established Treatment and Evidence Limits
The International League Against Epilepsy and the World Health Organization have endorsed phenobarbital use in poor countries through epilepsy demonstration projects. A review cautions that simply conducting more observational studies or non-randomized open trials cannot resolve the central evidence and implementation issues. A 2021 systematic review searched CENTRAL, Embase, PubMed, and Web of Science through December 15, 2020, for randomized controlled trials comparing phenobarbitone with other antiseizure medicines as first-line neonatal seizure therapy.
A Century of Antiseizure Therapy
Phenobarbital was first used as an antiepileptic drug in 1912, making its clinical history more than a century long. Historical accounts describe its discovery as a watershed moment that ushered in targeted pharmacotherapy for epilepsy and helped lay the groundwork for later generations of antiseizure drugs. Technical histories also trace the path from barbiturate chemical synthesis to the anticonvulsant discovery and the seminal clinical work of Alfred Hauptmann.
The Case Study: A Closer Look
The study focuses on a patient who, while undergoing treatment with phenobarbital for epilepsy, tragically died as a result of drowning. Post-mortem toxicology reports revealed that the patient had supra-therapeutic levels of phenobarbital in their system.
- CNS depression slows down brain activity, impacting vital functions such as breathing and heart rate.
- It can also impair cognitive and motor functions, reducing a person's ability to react quickly and maintain coordination.
- This impairment directly contributed to the patient's inability to stay afloat, ultimately leading to drowning.
Current Reviews and Mechanisms
A September 1, 2025 publication presents an updated systematic review and meta-analysis comparing phenobarbital with valproate for generalized convulsive status epilepticus in adults. Phenobarbital is a long-acting barbiturate used to treat and prevent several seizure types, including seizures in people with epilepsy. Its principal action is described as enhancement of the inhibitory neurotransmitter gamma-aminobutyric acid at the GABA-A receptor.
Limited Drowning Literature
The PubMed search for “phenobarbital drowning” lists indexed results in 1978, 1979, 1982, 1986, 1992, and 2009. It shows two results for 2009 and one result for each of the earlier listed years. The same search display shows zero results for 2026, so the listing does not establish a current or comprehensive evidence base about phenobarbital and drowning.
Available Product Information
The DailyMed search results page for phenobarbital reports 120 results. This figure describes the number of search results returned for the term “phenobarbital” on that page. Because the supplied result is a search listing rather than a comparative study, it does not by itself establish differences in effectiveness, safety, or drowning risk between phenobarbital and another treatment.
Staying Safe: Precautions and Awareness
The case study serves as a stark reminder of the potential risks associated with phenobarbital and similar medications. While these drugs can be life-saving for those with epilepsy, it's crucial to be aware of the side effects and take necessary precautions. Patients should be closely monitored for signs of CNS depression, and alternative treatments should be considered if adverse effects become too severe. Open communication between patients, caregivers, and healthcare providers is essential for ensuring the safe and effective use of phenobarbital.
Evidence From Experimental Status Epilepticus
A review describes research into long-term outcome and the development of chronic epilepsy after status epilepticus. In that work, rats with limbic status epilepticus received phenobarbital, MK-801, or phenytoin at 1, 2, and 4 hours after status epilepticus onset. The treatments were studied using continuous hippocampal stimulation.
Market and Practice Outlook
A 2026-2030 market report identifies continued use in epilepsy and neonatal seizure management as a major forecast-period trend. It also points to increasing availability of generic phenobarbital, greater focus on cost-effective anticonvulsant therapies, expansion of hospital-based seizure management, and increased monitoring of long-term drug safety. Another market outlook describes the future as a combination of stable core demand from epilepsy management and incremental innovation shaped by technological and regulatory changes.
Safety Concerns and Regional Use
Phenobarbital’s value in treating status epilepticus is described as controversial. The review reports that phenobarbital has fallen out of favor in many European countries because of reports of hypotension, arrhythmias, and hypopnea. At the same time, it describes phenobarbital as having a strong antiseizure effect with remarkably little sedation.
Individual and Palliative Applications
A 2021 case report describes a child with epilepsy with myoclonic absences that was resistant to multiple commonly used antiseizure medicines. In that case, low-dose phenobarbital unexpectedly achieved complete remission of epilepsy. Separate case reports describe phenobarbital as useful for end-of-life seizures and agitation, with administration through different modes in various palliative-care settings.